Neurodegenerative diseases represent a significant challenge in medical science, impacting millions globally. Despite advancements in diagnostic technology, ...

Lorem, a nonprofit foundation, today announced that nine patients with an ultra-rare type of amyotrophic lateral sclerosis (ALS) have been treated during the first year of a multi-year grant from the ...

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her ...

ALS Canada has named 39 Canadians to receive the King Charles III Coronation Medal for their efforts into research and advocacy for ALS.

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...